Integrative Proteomic and Phosphoproteomic Analyses of Pattern- and Effector-Triggered Immunity in Tomato

Plants have evolved a two-layered immune system consisting of pattern-triggered immunity (PTI) and effector-triggered immunity (ETI). PTI and ETI are functionally linked, but also have distinct characteristics. Unraveling how these immune systems coordinate plant responses against pathogens is crucial for understanding the regulatory mechanisms underlying plant defense. Here we report integrative proteomic and phosphoproteomic analyses of the tomato-Pseudomonas syringae (Pst) pathosystem with different Pst mutants that allow the dissection of PTI and ETI. A total of 225 proteins and 79 phosphopeptides differentially accumulated in tomato leaves during Pst infection. The abundances of many proteins and phosphoproteins changed during PTI or ETI, and some responses were triggered by both PTI and ETI. For most proteins, the ETI response was more robust than the PTI response. The patterns of protein abundance and phosphorylation changes revealed key regulators involved in Ca2+ signaling, mitogen-activated protein kinase cascades, reversible protein phosphorylation, reactive oxygen species (ROS) and redox homeostasis, transcription and protein turnover, transport and trafficking, cell wall remodeling, hormone biosynthesis and signaling, suggesting their common or specific roles in PTI and/or ETI. A NAC (NAM, ATAF, and CUC family) domain protein and lipid particle serine esterase, two PTI-specific genes identified from previous transcriptomic work, were not detected as differentially regulated at the protein level and were not induced by PTI. Based on integrative transcriptomics and proteomics data, as well as qRT-PCR analysis, several potential PTI and ETI-specific markers are proposed. These results provide insights into the regulatory mechanisms underlying PTI and ETI in the tomato-Pst pathosystem, and will promote future validation and application of the disease biomarkers in plant defense.

Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer

Background Ovarian cancer is the leading cause of death from gynaecologic illnessed worldwide. Platelet-activating factor acetyl hydrolase IB2 (PAF-AH IB2) is an intracellular serine esterase that hydrolyzes platelet-activating factor, a G-protein-like trimer with two catalytic subunits and one regulatory subunit. The regulatory role of PAF-AH IB2 in the oncogenesis of ovarian cancer is not well understood. Methods In this study, the TCGA dataset and clinical cancer tissue microarray were utilized to investigate abnormal overexpression of PAF-AH IB2 in ovarian cancer. To investigate the impact on the cell proliferation, migration, and tumorigenicity in vitro, PAF-AH IB2 stable knocking down (KD) ovarian cancer cells were established by ShRNA. The whole transcription profiling, tyrosine kinase profiling and standard cell functional assays were integrated to explore the biological importance and mechanism of PAF-AH IB2 modulated in ovarian cancer. Results PAF-AH IB2 was identified significantly overexpression in four subtypes of ovarian cancer. In vitro, PAF-AH IB2 KD significantly inhibited cancer cell proliferation, migration, and tumorigenicity, activated caspases and caused cell cycle arrest, and made the cells more sensitive to PAF. PAF-AH 1B2 KD cells down-regulated several key regulators of the multiple tyrosine kinases-mediated signaling pathway, suggesting a novel interaction network between the growth factor receptors pathway and PAF-AH 1B2 mediated PAF signalling. Conclusions These findings revealed a previously undiscovered role for PAF-AH IB2 as a potenial therapy target and essential signaling mediators in ovarian cancer pathogenesis, as well as new possible preventive and therapeutic strategies to inhibit this enzyme in clinical treatment for ovarian cancer.

Platelet-activating Factor Acetyl Hydrolase IB2 Dysregulated Cell Proliferation in Ovarian Cancer

BackgroundOvarian cancer is the world’s largest cause of death for gynaecologic diseases. Platelet-activating factor acetyl hydrolase IB2 (PAF-AH IB2) is an intracellular serine esterase that hydrolyzes platelet-activating factor, a G-protein-like trimer with two catalytic subunits and one regulatory subunit. The deregulatory role of PAF-AHIB2 in the etiology of ovarian cancer is poorly understood. MethodsIn this study, the TCGA exploration and cancer tissue immunohistochemistry were utilized to investigate aberrant overexpression of PAF-AH IB2 in ovarian cancer. PAF-AH IB2 Stable knocking down (KD) ovarian cancer cells were established to investigate the impact on the cell proliferation, migration, and tumorigenicity in vitro. The whole transcription profiling, tyrosine kinase profiling and standard cell functional assays were integrated to explore the biological importance and mechanism of PAF-AH IB2 modulated in ovarian cancer. ResultsInteresting, PAF-AH IB2 was identified significantly overexpression in four subtypes of ovarian cancer. PAF-AHIB2 KD significantly reduced cancer cell proliferation, migration, and tumorigenicity in vitro, activated Caspases and caused cell cycle arrest, and making the cells more sensitive to PAF. Several key regulators of multiple tyrosine kinases-mediated signaling pathway were down-regulated in PAF-AH 1B2 KD cells, revealing a novel interaction network between the growth factor receptors pathway and PAF-AH 1B2 mediated PAF signalling.Conclusions These results discovered an unrevealed role for PAFAH IB2 as a novel potential therapy target and essential signaling mediators in ovarian cancer pathogenesis, as well as new potential preventive and therapeutic strategies to inhibit this enzyme in clinical treatment for ovarian cancer.

GENDER SPECIFIC CHANGES IN MOUSE BLOOD ESTRERASE PROFILE AT THE ACUTE INTOXICATION BY 2-(О-CRESYL)-4Н-1,3,2-BENZODIOXAPHOSPHORIN-2-OXIDE

A comparative investigation of the esterase profiles of blood of mice of both genders exposed to various doses of 2-(o-crezyl)-4H-1,3,2-benzodioxaphosphorin-2-oxide (CBDP) was made an hour after its percutaneous injection to animals. A lesser amount of esterase in males blood made them more susceptible to CBDP action as compared to females. It was shown that CBDP equally inhibits the activity of carboxyl esterase and butyryl choline esterase in blood serum of both male and female mice. Statistically significant differences in inhibition degree of enzymes between males and females were found out and therefore it is not recommended to use mixed groups of animals when performing testing of serine esterase inhibitors.